Aleva Neurotherapeutics

Aleva Neurotherapeutics is a Swiss medical device company headquartered in Lausanne, Switzerland, focused on advancing deep brain stimulation (DBS) therapy for patients with Parkinson's disease and other movement disorders. The company has developed its proprietary directSTIM technology, a directional DBS lead system that enables clinicians to steer electrical stimulation with precision toward specific neural targets. Unlike traditional omnidirectional DBS leads, directSTIM allows for highly selective activation of therapeutic brain regions while avoiding stimulation of adjacent structures that can produce unwanted side effects. This level of targeting represents a meaningful clinical advancement in how neuromodulation therapy is delivered and personalized for individual patients.

Aleva has secured Series C funding totaling $35 million, reflecting sustained investor confidence in both its technology platform and the broader growth trajectory of the DBS market. The company has progressed its directSTIM lead system through rigorous development and clinical evaluation stages, positioning itself as a competitive player among established DBS device manufacturers. Their Lausanne base provides access to a strong European medtech ecosystem, supporting both engineering innovation and regulatory pathway execution. The funding milestones indicate that Aleva is advancing toward broader clinical adoption and potential commercialization at scale.

Aleva Neurotherapeutics matters to the neurotech industry because it exemplifies the shift toward more precise, patient-tailored neurostimulation therapies. As the global DBS market continues to expand alongside rising Parkinson's disease prevalence, companies that can demonstrate superior clinical outcomes through directional control of stimulation are well positioned to reshape treatment standards. Their work also contributes to a broader industry movement toward intelligent, adaptable implantable devices that respond to the complex and variable nature of neurological conditions. By pushing the boundaries of lead design and stimulation specificity, Aleva is helping to define what next-generation neuromodulation can and should look like.